Video

The Evolution of AR Pathway Inhibitors and Docetaxel Utilization in mCRPC Treatment and the Impact on Cabazitaxel

Author(s):

Neal Shore, MD, FACS

Neal Shore, MD, FACS, speculates on how the utilization of AR-pathway inhibitors and docetaxel in earlier lines of mCRPC treatment has also influenced treatment with cabazitaxel.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected

      Newsletter

      Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

      Subscribe Now!
      Related Videos
      Alicia Morgans, MD, on QOL outcomes with darolutamide plus ADT in mHSPC
      Alicia Morgans, MD, on QOL outcomes with darolutamide plus ADT in mHSPC
      Blur image of hospital corridor | Image Credit: © zephyr_p - stock.adobe.com
      Post-RP incontinence: Low procedure rates examined
      Bashir Al Hussein Al Awamlh, MD, MPH, answers a question during a Zoom video interview
      Data link incontinence severity to post-radical prostatectomy care
      Jim Hu, MD, on upgrading of GG1 prostate cancer at radical prostatectomy
      Jim Hu, MD, on upgrading of GG1 prostate cancer at radical prostatectomy
      Man talking with a doctor | Image Credit: © Chinnapong - stock.adobe.com
      Expert discusses differentiating prostate cancer from age-related issues
      Murilo De Almeida Luz, MD, on PSA and ALP changes with enzalutamide/radium-223
      Murilo De Almeida Luz, MD, on PSA and ALP changes with enzalutamide/radium-223
      Ruben Olivares, MD, answers a question during a Zoom video interview
      Ruben Olivares, MD, discusses remote robot–assisted HIFU for prostate cancer
      Doctor consulting patient | Image Credit: © Liudmila Dutko - stock.adobe.com
      Strategies to bridge gender disparities in AAS and citations in the oncology literature
      Stacy Loeb, MD, MSc, PhD (Hon), answers a question during a Zoom video interview
      Stacy Loeb, MD, MSc, PhD (Hon), discusses the nuances of prostate cancer screening
      1 expert in this video
      Selecting Between Receptor Pathway Inhibitors for mHSPC
      Related Content
      FDA greenlights phase 1 trial of theranostic radiopharmaceutical for mCRPC
      June 20th 2025

      FDA greenlights phase 1 trial of theranostic radiopharmaceutical for mCRPC

      Hannah Clarke
      The phase 1 study is set to begin later this year.
      Pearls & Perspectives: Helen Bernie, DO, MPH, at AUA 2025 | Credit: Urology Times
      April 27th 2025

      Pearls & Perspectives: Helen Bernie, DO, MPH, at AUA 2025

      Amy M. Pearlman, MD Helen L. Bernie, DO, MPH
      Helen Bernie, DO, MPH, joins the show to discuss data from her Indiana University team from the floor at AUA 2025.
      Real-world studies compare overall survival between ARPIs in mCSPC
      June 19th 2025

      Real-world studies compare overall survival between ARPIs in mCSPC

      Mehmet Asim Bilen, MD Hannah Clarke
      "Overall, these findings add to the growing body of evidence that [shows that] apalutamide may offer a survival advantage in real-world setting in patients with metastatic castration-sensitive prostate cancer," says Mehmet A. Bilen, MD.
      Dr. Murphy on increasing diversity in cancer clinical trials
      February 29th 2024

      Dr. Murphy on increasing diversity in cancer clinical trials

      Urology Times staff
      In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.
      Study to evaluate impact of ArteraAI on clinical decision-making for prostate cancer
      June 17th 2025

      Study to evaluate impact of ArteraAI on clinical decision-making for prostate cancer

      Hannah Clarke
      ArteraAI is a multimodal artificial intelligence biomarker test that can predict therapy benefit and prognosticate long-term outcomes in prostate cancer.
      FDA does not approve talazoparib plus enzalutamide for non-HRR gene mutated mCRPC
      June 17th 2025

      FDA does not approve talazoparib plus enzalutamide for non-HRR gene mutated mCRPC

      Hannah Clarke
      Pfizer has chosen to no longer pursue an expanded indication for talazoparib plus enzalutamide in non-HRR gene mutated mCRPC in the US as a result of this decision.
      © 2025 MJH Life Sciences

      All rights reserved.